

Counteracting the Disease Continuum in Hormone-Sensitive Prostate Cancer

Tweetorial #2 References

Tweet 3

Svensson J, Lissbrant IF, Gauffin O, et al. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. *Scand J Urol*. 2021;55(1):1-8. doi:10.1080/21681805.2020.1851762

Tweet 5

Virgo KS, Rumble RB, De Wit R, et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. *J Clin Oncol*. 2021;39(11):1274-1305. doi:10.1200/jco.20.032561.

Attard G, Brown LC, Clarke N, et al. LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. *Ann Oncol*. 2021;32:S1298. doi:10.1016/j.annonc.2021.08.2098

Fizazi K, Carles Galceran J, Foulon S, et al. LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1. *Ann Oncol*. 2021;32:S1299. doi:10.1016/j.annonc.2021.08.2099

Sweeney CJ, Beltran H. The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data. *Eur Urol*. 2019;76(6):729-731. doi:10.1016/j.eururo.2019.09.017

Tweet 6

Agarwal N. Advances in metastatic castration-sensitive prostate cancer. Episode 6: AR therapy early intervention & the future of CRPC treatment. Targeted Oncology. July 17, 2019. Accessed January 25, 2021. <https://www.targetedonc.com/view/metastatic-crpc?seriesVid=6>

Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. *N Engl J Med*. 2019;381:13-24.

Chi KN, Chowdhury S, Bjartell A, et al. Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). *J Clin Oncol*. 2021;39(6_suppl):1-11. doi:10.1200/JCO.2021.39.6_suppl.11

Agarwal N, McQuarrie K, Bjartell A, et al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. *Lancet Oncol*. 2019;20:1518-1530.

Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. *N Engl J Med*. 2018;378:1408-1418.

Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*. 2019;380:1235-1246.

Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. *N Engl J Med*. 2019;381:121-131.

Armstrong AJ, Szmuelwitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. *J Clin Oncol*. 2019;37:2974-2986.

Hussein M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*. 2018;378:2465-2474.

Tweet 7

Freedland SJ, De Giorgi U, Gleave M, et al. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. *BMJ Open*. 2021;11(8):e046588. doi:10.1136/bmjopen-2020-046588

Tweet 10

Freedland SJ, De Giorgi U, Gleave M, et al. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. *BMJ Open*. 2021;11(8):e046588. doi:10.1136/bmjopen-2020-046588

ClinicalTrials.gov. Safety and efficacy study of enzalutamide plus leuprolide in patients with nonmetastatic prostate cancer (EMBARK). NCT02319837. Updated April 23, 2021. Accessed August 17, 2021. <https://clinicaltrials.gov/ct2/show/NCT02319837?term=NCT02319837&draw=2&rank=1>

Tweet 11

Hadaschik BA, Fanti S, Ost P, et al. 649TiP - PRIMORDIUM: A randomized, international, trial-in-progress of adding apalutamide to radiotherapy and an LHRH agonist in high-risk patients with PSMA-PET-positive hormone-sensitive prostate cancer. *Ann Oncol*. 2021;32(suppl_5):S626-S677. doi:10.1016/annonc/annonc702

ClinicalTrials.gov. A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants (PRIMORDIUM). NCT04557059. Updated July 23, 2021. Accessed August 17, 2021. <https://clinicaltrials.gov/ct2/show/NCT04557059>

Tweet 12

Aggarwal RR, Eggener SE, Chen RC, et al. A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19). *J Clin Oncol*. 2018;36(15_suppl):TPS5090. doi:10.1200/JCO.2018.36.15_suppl.TPS5090

ClinicalTrials.gov. A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer. NCT03009981. Updated May 29, 2019. Accessed August 31, 2021.
<https://clinicaltrials.gov/ct2/show/study/NCT03009981>

Tweet 14

ClinicalTrials.gov. The role of highly selective androgen receptor (AR) targeted therapy in men with biochemically relapsed hormone sensitive prostate cancer. NCT01790126. Updated March 11, 2020. Accessed August 18, 2021.
<https://clinicaltrials.gov/ct2/show/study/NCT01790126?term=apalutamide&cond=hormone+sensitive+prostate+cancer&phase=1&draw=2&rank=1>

XTANDI® (enzalutamide) [prescribing information]. Astellas Pharma US, Inc. Approved 2012. Revised May 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213674s002lbl.pdf

ZYTIGA® (abiraterone acetate) [prescribing information]. Janssen Biotech, Inc. Approved 2011. Revised October 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202379s031s033lbl.pdf

Tombal B, Borre M, Rathenborg P, et al. Enzalutamide monotherapy in hormone-naïve prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. *Lancet Oncol*. 2014;15(6):592-600. doi:10.1016/S1470-2045(14)70129-9

Rice MA, Malhotra SV, Stoyanova T. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. *Front Oncol*. 2019;9(801):801. doi:10.3389/fonc.2019.00801

Tweet 15

Sweeney CJ, Beltran H. The balancing act: assessing treatment burden versus treatment benefit with evolving metastatic hormone-sensitive prostate cancer data. *Eur Urol*. 2019;76(6):729-731. doi:10.1016/j.eururo.2019.09.017

Weiner AB, Netter OS, Morgans AK. Management of metastatic hormone-sensitive prostate cancer (mHSPC): an evolving treatment paradigm. *Curr Treat Options Oncol*. 2019;20(9):69. doi:10.1007/s11864-019-0668-8

Glossary

AAP, abiraterone acetate plus prednisolone
ABI, abiraterone
ADT, androgen deprivation therapy
AE, adverse event
APA, apalutamide
AR, androgen receptor
ASCO, American Society of Clinical Oncology
BCR, biochemical relapse
BMD, bone-mineral density
BRPC, biochemically recurrent prostate cancer
CT, computed tomography
ENZ, enzalutamide
HR, hazard ratio
HSPC, hormone-sensitive prostate cancer
HV, high volume
LHRHa, luteinizing hormone releasing hormone analog
mCRPC, metastatic castration-resistant prostate cancer
Metach, metachronous
MFS, metastasis-free survival
mHSPC, metastatic hormone-sensitive prostate cancer
mMFS, median metastasis-free survival
MPFS, metastatic progression-free survival
nmCRPC, nonmetastatic castration-resistant prostate cancer
nmHSPC, nonmetastatic hormone-sensitive prostate cancer
OS, overall survival
PBO, placebo
PCa, prostate cancer
PET, positron emission tomography
pGS, polygenic score

PFS, progression-free survival

Ph, phase

PSA, prostate specific androgen

PSADT, PSA doubling time

PSMA, prostate-specific membrane antigen

QOL, quality of life

RCT, randomized controlled trial

RP, radical prostatectomy

RT, radiation therapy

TST, testosterone

TTR, time to relapse

w/, with